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Background: As the Coronavirus Disease 2019 (COVID-19) pandemic grows 
daily, we remain with no prophylactic and only minimal therapeutic 
interventions to prevent or ameliorate severe acute respiratory syndrome 
Coronavirus 2 (SARS-CoV-2). Prior to SARS-CoV-2 emergence, high throughput 
screens utilizing clinically developed drugs identified compounds with in vitro 
inhibitory effect on human coronaviruses that may have potential for 
repurposing as treatment options for COVID-19. However, caution should be 
applied to repurposing of these drugs when they are taken out of context of 
human pharmacokinetic parameters associated with normal therapeutic use. 
Methods: Our aim was to provide a tier-based scoring system to interrogate this 
data set and match each drug with its human pharmacokinetic criteria, such as 
route of administration, therapeutic plasma levels and half-life, tissue 
distribution, and safety. 
Results: Our analysis excluded most previously identified drugs but identified 
members of 4 drug classes (antimalarial amino-quinolones, selective estrogen 
receptor modulators; SERMs, low potency tricyclic antipsychotics and tricyclic 
antidepressants) as potential drug candidates for COVID-19. Two of them, the 
tricyclic antipsychotics and tricyclic antidepressants were further excluded 
based on a high adverse event profile. 
Conclusions: In summary, our findings using a new pharmacokinetic-based 
scoring system supports efficacy testing of only a minority of candidates 
against SARS-CoV-2 infection.  
 
Currently, there is no licensed treatment for COVID-19 worldwide, but the FDA has 
recently given emergency approval for the use of Remdesivir in COVID-19 patients 
[1]. In addition, over 1000 clinical trials are currently ongoing or in set-up mode in 
different countries, including drugs such as lopinavir/ritonavir, dexamethasone, 
hydroxychloroquine and inhaled interferon beta-1a [2]. Overall, the current situation is 
far less than satisfying and there is an urgent need for additional treatment options, 
especially as the pandemic moves into lower resourced countries.  
 
 
Over the past decade, several studies have used high throughput screens 
(HTS) to identify clinically developed drugs with in vitro inhibitory capacity against 
human coronaviruses (hCoVs) that may have potential for repurposing as prophylactic 
or therapeutic treatment options for hCoV infections. These HTS have identified >60 
drugs with inhibitory effect as measured by reduction of replication of multiple hCoVs 
in a variety of different mammalian cell types in vitro. However, candidates are rarely 
considered in light of their pharmacokinetic parameters associated with normal 
therapeutic dosing. The aim of our study was to use a tier-based scoring system to 
interrogate this data set by matching drugs with their respective human 
pharmacokinetic criteria as well as their safety and systemic side effects relevant 
within the COVID-19 patient setting, allowing us to exclude identified HTS candidates 
based on these defined pharmacokinetic criteria. Remaining candidates were then 
further considered based on potential for adverse effects within the COVID-19 patient 
treatment environment.  
Screening clinically approved pharmaceuticals for repurposing removes the 
substantial time burden associated with movement of experimental drugs from 
preclinical stage through the regulatory pathway to approval. Repurposing can be 
especially important for the rapid identification of candidate drugs against emerging 
infectious diseases such as the present pandemic COVID-19. With notable exceptions 
[3], only a few drugs have been successfully repurposed, and none for the prevention 
or treatment of virus infection. With this in mind, our tier-based analysis used three 
HTS studies as a source of clinically developed drugs with inhibitory effect against in 
vitro replication of multiple hCoVs [4-6]. Drug candidates were critically examined 
based on the following key pharmacokinetic parameters: route of normal 
administration, therapeutic plasma levels and half-life, tissue distribution, and safety 
and adverse reactions. Availability and cost were additional important parameters 
given the anticipated need for treatment options within low- and middle-income 
countries. These characteristics were used to i) remove candidates based on 
pharmacokinetic parameters and potential for adverse events not consistent with 
prophylactic/therapeutic use for COVID-19, and ii) prioritize remaining drugs for 
possible in vitro confirmation of SARS-CoV-2 inhibitory activity and movement into 
preclinical animal models (Tier 1 and Tier 2) (Table 1 and Table 2). Tier 1 represents 
drug candidates with administration, pharmacokinetic and safety parameters suitable 
for movement into preclinical models; Tier 2 represents similarly suitable candidates, 
but with a higher adverse event profile. Drugs in Tier 3 have a lower priority due to 
higher risk of complications in the COVID-19 patient setting, and Tier 4 drugs are those 
with low prophylactic/therapeutic potential against COVID-19 and/or with high 
potential for adverse effects (Supplemental Table 1).  
In the study of de Wilde et al (2014) [5], a 348 FDA-approved drug library was 
screened for inhibitory activity against Middle East respiratory syndrome CoV (MERS-
CoV), with those identified with high inhibitory effect (EC50 at low micro-molar 
concentrations) being tested further for activity against SARS-CoV-1 and hCoV-229E. 
This HTS resulted in identification of 4 candidates with low micro-molar EC50 
concentrations against these 3 hCoVs and low cellular toxicity. The Dyall et al (2014) 
study [6] screened by HTS a library of 290 FDA-approved, or experimental drugs with 
defined molecular targets, that had previously shown activity against RNA viruses 
[7,8]. The study identified 27 compounds with inhibitory activity against MERS-CoV 
and SARS-CoV-1 with EC50 levels in the low micro-molar range with minimal 
cytotoxicity. The 2019 HTS of Shen et al (2019) [4] screened a 2,000-component 
library of FDA-approved and pharmacologically active compounds. Seven compounds 
 
 
were identified with an EC50 of <5 M against 4 distinct hCoVs. For the purpose of our 
study, we expanded the inclusion criteria of Shen et al (2019) [4] to include a total of 
36 compounds with an EC50 of <20M for the four hCoVs and low cytotoxicity. 
Together, our analysis was comprised of a total of 58 compounds. We excluded 26 
compounds, and identified 11 and 21 compounds with high and medium priority, 
respectively, with potential for therapeutic intervention against COVID-19. In addition 
to the single HIV protease inhibitor, lopinovir, the high priority (Tier 1 and Tier 2) 
compounds represented multiple members from four key drug classes: antimalarial 
quinolones, selective estrogen receptor modulators (SERMs), amine tricyclic 
antipsychotics, and amine tricyclic antidepressants.  
After removal of primarily experimental agents or those with high toxicity, 
pharmacokinetic parameters of therapeutic plasma levels of normal dosing and 
plasma half-life were used as an initial measure to assess whether hCoV inhibitors 
reach levels required for virus inhibition within the patient. For example, loperamide, 
an antidiarrheal agent identified as an attractive candidate for repurposing in two HTS 
screens [4,5] has therapeutic plasma levels >3 orders of magnitude lower than its EC50 
against any hCoV tested [9]. This assessment resulted in removal of 26 candidates; 
drugs applied topically were also removed. Although multiple antipsychotics were 
identified by HTS as broad inhibitors of hCoV replication in vitro, only the low potency 
1st generation tricyclics reached the necessary therapeutic plasma levels for inclusion 
(Tier 2), with the more potent later generation tricyclics commonly orders of magnitude 
below their EC50.    
Four distinct but structurally related members of the antimalarial quinolone 
class displayed inhibitory effects on multiple hCoVs. Normal therapeutic levels of 
these agents reached plasma levels approximating the identified EC50 in the HTS 
studies. Lung tissue distribution (when available) was used as a further parameter, 
wherein lung tissue-specific accumulation was regarded as a positive indicator for 
potential therapeutic effect. Based on available data, the quinolone compounds have 
been shown to accumulate at high (~1000-fold) levels in the lung compared to plasma. 
Consistent with the prophylactic use of quinolones against malaria, most members 
exhibit a long plasma half-life, with oral administration being the preferred route to 
prevent toxicity associated with more rapid parenteral routes. Amongst the quinolones, 
however, amodiaquine and mefloquine were listed in Tier 2, as compared to other 
members, these drugs are associated with more severe and prolonged adverse 
reactions (Table 2). Other high priority candidates with therapeutic plasma levels 
approaching necessary EC50 levels were the selective estrogen receptor modulators 
(SERMs) (tamoxifen and toremifene), amine tricyclic antidepressants (clomipramine 
and desipramine), and low potency tricyclic antipsychotics (promazine and 
chlorpromazine). The SERMs in particular showed high accumulation within the lung 
and minimal adverse reactions, and were listed in Tier 1 (Table 1). In contrast, due to 
a higher number of associated adverse reactions, as well as the frequent need for 
optimization of the dosing regimen, the antidepressants and antipsychotics were listed 
in Tier 2 (Table 2) [9-11].   
  Multiple hCoV inhibitory drugs identified by HTS with attractive pharmacokinetic 
profiles were prioritized lower (Tier 3) due to either their preclinical/experimental status 
or higher possibility for adverse reactions in the COVID-19 patient setting; otherwise 
attractive candidates with short half-lives were also included in this tier (Supplemental 
Table 1). Several antineoplastic agents were identified that interfere with DNA and 
RNA replication. The prodrug mycophenolate mofetil, through its mycophenolic acid 
active metabolite, is an inhibitor of guanosine synthesis through an inhibitory effect on 
 
 
inosine monophosphate dehydrogenase; gemcitabine and hycanthone both inhibit 
DNA and RNA synthesis directly through distinct mechanisms. Depending on the 
dosage, these anti-neoplastic drugs can result in a level of immune suppression that 
may be contraindicated for use in COVID-19 patients, where adaptive immunity will 
presumably be important. Dasatinib and imatinib, small molecule inhibitors of the Abl 
tyrosine kinase pathway, also fell within Tier 3 for this reason. Metronomic dosing to 
achieve plasma levels above the EC50, but below the immunosuppressive dose may 
achieve the necessary level of virus inhibition without undermining patient adaptive 
immune responses. Such a treatment scenario would need to be assessed in a 
preclinical animal model before moving to clinical studies. 
Timing of therapeutic intervention against SARS-CoV-2 appears to be critical, 
with disease etiology changing over time: disease being a more direct effect of virus 
replication at early times, whilst later lung pathology being host immune response-
driven. The HTS studies detailed above identify compounds based on inhibition of 
hCoV replication. Drug candidates are therefore expected to be more effective for 
COVID-19 disease management when used early. Studies using Remdesivir (GS-
5734; hCoV polymerase inhibitor) highlight the altering course of disease over time 
and the importance of instigating antiviral measures early. Later drug administration 
reduced virus replication, but failed to improve lung function or disease outcome in the 
immunopathologic-driven stage of disease [12]. This key importance of timing may be 
a possible explanation for inconsistent results from recent and ongoing studies 
investigating repurposing of drugs such as hydroxychloroquine, which again 
emphasizes the need for preclinical animal challenge models before progression to 
human clinical trials. 
To be useful clinically, drugs will need to have a minimal adverse event profile 
(particularly for prophylaxis); not be contraindicated in patients who have underlying 
medical conditions; and achieve therapeutic drug concentrations rapidly. The low 
potency tricyclic antipsychotics do not possess these attributes; both chlorpromazine 
and promazine need to be carefully titrated to optimal therapeutic doses, and many 
patients report a plethora of adverse events. Furthermore, they are contraindicated in 
patients with multiple co-morbidities which place these patients into the COVID-19 
vulnerable category. The amine tricyclic anti-depressants clomipramine and 
desipramine face similar challenges. Half of treated patients may report somnolence 
and dizziness aside of other adverse events. Patients with underlying medical 
conditions are either more likely to experience some of these class toxicities (e.g. 
glaucoma, urinary retention from their anti-cholinergic properties) or be 
contraindicated. Furthermore, they show potential for overdose misuse and suicidal 
ideation as well as withdrawal symptoms even after short courses of treatment.  
The protease inhibitor lopinavir, the SERMS tamoxifen and toremifene and the 
anti-malarials chloroquine and hydroxychloroquine have wider therapeutic indices 
than the tricyclic drugs and have decades of widespread clinical use across 
geographies, patient demographics and co-morbidities. Lopinavir’s recommended 
daily dose for HIV-1 infection (800mg) produces plasma levels covering the EC50 
values for pathogenic hCoVs. Tamoxifen and toremifene are customarily used at daily 
doses of 20mg and 60mg, respectively, for breast cancer. But higher daily doses 
(~600mg and 680mg, respectively) are relatively well tolerated under short durations 
reaching plasma concentrations after a single dose at anti-viral EC50 levels and 
evidence of greater concentrations within tissue.  
COVID-19 is a rapidly evolving situation. During review of the manuscript some 
of the drugs under consideration were tested for in vitro inhibitory activity against 
 
 
SARS-CoV-2, which is shown in the accompanying tables (Table 1 & 2 and 
Supplemental Table 1). During this time, two pre-clinical animal studies have also 
reported the absence of any effect of hydroxychloroquine when used either 
prophylactically or therapeutically against SARS-CoV-2 replication or associated 
disease [13,14]. Hydroxychloroquine treatment was also recently removed from the 
WHO Solidarity COVID-19 clinical study based on evidence from the Solidarity trial, a 
Cochrane review of the drug as well as on the release of a report from the UK-based 
RECOVERY trial where hydroxychloroquine showed no effect on mortality rate of 
COVID-19 patients [15,16]. Similarly, a post-exposure prophylaxis trial showed no 
effect of hydroxychloroquine on the incidence of infection from high and moderate-risk 
exposure to SARS-CoV-2 [17]. Multiple pre-exposure prophylaxis trials remain 
ongoing [18]. New recent data has also shed light on a possible mechanism behind 
the apparent divergence in inhibitory effect of hydroxychloroquine between in vitro and 
in vivo studies;  wherein, the virus uses a distinct entry pathway in the Vero cells 
standardly used for in vitro determination of drug sensitivity, compared to the pathway 
utilized in lung epithelium in vitro and presumably in vivo. Notably, only the entry 
pathway in Vero cells is susceptible to inhibition by endosomal pathway inhibitors such 
as hydroxychloroquine [19,20].   
In summary, caution should be applied to repurposing of drugs when they are 
taken out of context of human pharmacokinetic parameters associated with normal 
therapeutic use. Our tier-based scoring system to analyze drugs identified through 
HTS with in vitro efficacy against one or more hCoVs resulted in the exclusion of the 
majority of compounds for further consideration. Similar to the quinolones, SERMs 
(i.e. tamoxifen and toremifene) are a class of drugs that have characteristics of low 
micro-molar hCoV inhibitory activity, attractive human pharmacokinetics, favorable 
tissue accumulation and good safety profile for use in COVID patients [9]. The next 
step for all potential candidates will be preclinical efficacy testing in animal models 
against SARS-CoV-2 challenge. Repurposing of clinically approved drugs helps 
remove the concern of overt drug toxicity. However, animal infection models are critical 
as they place the treatment within the context of the kinetics of virus infection within 
the host. They can also identify unexpected enhancement of disease by a drug in 
context of viral infection, as experienced with mycophenolate mofetil against MERS-
CoV in nonhuman primates [21]. A similar enhancement effect was seen for 
chloroquine prophylaxis but not treatment of mosquito-transmitted chikungunya, which 
corresponded with an immunomodulatory effect of the drug, and again emphasizes 
the importance of timing in therapeutic intervention [22].  
Finally, combinations of drugs are often far more effective than single 
compounds [23]. Therefore, these Tier 1 drugs should be considered for combined 
use to take advantage of possible synergy between drugs with differing modalities of 
virus inhibition. However, unpredicted antagonism can also result from such 
combinations, as was recently observed between chloroquine and Remdesivir [24]. 
Again, such studies initially need to be performed using in vitro cell systems and, 
importantly, preclinical animal models prior to considering movement into humans.   
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Name of Drug                           
(mol. wt. g/mol)
Plasma Levels & Lung 
Distribution Half-life
EC50, CC50 (µM) Reason for Tier Designation
Dasatinib1                                      
(488.0)
Oral administration of 100mg results 
in 104ng/ml (0.2uM).10 Accumulates 
(15-fold) in lung compared to 
plasma.11 
< 4 h10 MERS(5.468); SARS(2.100)1
Pros: 1) Lung levels within range of 
EC50 2) Good clinical experience                                                    
Cons: 1) Short half-life 2) Potential 
immune suppression (potential for 
metronomic dosing)
Imatinib mesylate1                                         
(589.7)
Following a 400mg oral dose given 
once daily to steady state peak 
plasma concentration of 1.8ug/ml 
(3.05uM) to 3.4ug/ml (5.76uM).4 
Lung accumulation is not known. 
22h4
MERS(17.689); SARS(9.823)1; SARS-
CoV-2(5.32, >30.86)40
Pros: 1) Lung levels within range of 
EC50 2) Good clinical experience                                                    
Cons: 1) Short half-life 2) Potential 
immune suppression (potential for 
metronomic dosing)
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Gemcitabine HCl1                         
(299.7)
Steady-state concentration during a 
10mg/m2 per min infusion for 120 
to 640 min is 26.9uM. Used for non-
small cell lung cancer indicating 
clinically significant lung 
localization.4
15 min to 1 h4 MERS(1.216); SARS(4.957)1
Pros: 1) Lung levels within range of 
EC50 2) Good clinical experience                                                    
Cons: 1) Short half-life 2) Potential 
immune suppression (potential for 
metronomic dosing)
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Hycanthone8                                 
(356.5)
Infusion of 60mg/m2 results in two 
patients resulted in peak plasma of 
1ug/ml (2.80uM) and following 
100mg/m2 a peak plasma of 
2.4ug/ml (6.73uM).12 Lung 
distribution not known.
3 to 5 hours12
OC43(0.16, 3.58); NL63(5.76, 3.68); 
MERS(5.11, 4.32); A59(5.78, 4.19)8
Pros: 1) Presume lung levels within 
range of EC50                                                                               
Cons: 1) Short half-life 2) Potential 
immune suppression (potential for 
metronomic dosing) 3) No clinical 
experience   
Mycophenolate 
mofetil8                  
(433.5)
Prodrug rapidly converted to active 
drug MPA (see below). See Below
OC43(1.58, 3.43); NL63(0.23, 3.01); 
MERS(1.54, 3.17); A59(0.27, 
3.33)8;SARS-CoV-2(0.47, >10) 41
Pros: 1) Lung levels within range of 
EC50 2) Good clinical experience 3) 
Suitable half-life                                                   
Cons: 1) Potential immune 
suppression (potential for 
metronomic dosing)
Mycophenolic acid 
(MPA)8                     
(320.3)
8ug/ml (24.97uM) to 19ug/ml 
(59.32uM) following a 1 to 1.75 g 
oral dose given twice daily to steady 
state in renal patients.4
11 to 24 h4
OC43(1.95, 3.55); NL63(0.18, 3.44); 
MERS(1.95, 3.21); A59(0.17, 4.18)8
Pros: 1) Lung levels within range of 
EC50 2) Good clinical experience 3) 
Suitable half-life                                                   
Cons: 1) Potential immune 
suppression (potential for 
metronomic dosing)
Alprenolol8                                     
(249.3)
Therapeutic levels 0.025ug/ml 
(0.10uM) to 0.14ug/ml (0.56uM).6 
High lung accumulation after IV 
administration, but only 2-fold 
after oral administration.13  
2 to 7 h6
OC43(1.95, >20); NL63(11.88, >20); 
MERS(10.53, >20); A59(13.97, >20)8
Pros: 1) Lung levels within range of 
EC50 2) High lung accumulation and 
be achieved (IV administration) 3) 
Good clinical experience                                                         
Cons: 1) Short half-life 
Propranolol8                                   
(259.3)
Therapeutic level 0.02ug/ml 
(0.07uM) to 0.3ug/ml (1.15uM).6 
Rabbits given a 10mg/kg 
subcutaneous dose had 250-fold 
higher levels of drug in lung than 
blood at 1h.14 In dogs given a 
4.5mg/kg dose over 45 min, 50-fold 
higher levels were present in lung 
compared to plasma.15
2 to 6 h6
OC43(0.48, >20); NL63(8.11, >20); 
MERS(11.01, >20); A59(13.54, >20)8
Pros: 1) Lung levels within range of 
EC50 2) High lung accumulation 3) 
Good clinical experience                                                               
Cons: 1) Short half-life 
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Doxazosin mesylate8                     
(547.6)
0.01ug/ml (.018uM) to 0.15ug/ml 
(0.27uM)6 Accumulation data not 
available, but prototype of family, 
prazosin, accumulates in lungs.16
20h4
OC43(4.97, >20); NL63(13.95, >20); 
MERS(12.66, >20); A59(14.48, >20)8
Pros: 1) At lower limit of EC50 
2)Parent, prazosin, accumulates 10-
fold in lungs                                Cons: 
1) At lower limit of EC50
Tier 3
Supplementary 
Table 1
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Papaverine8                                 
(339.4)
Based on 80mg oral dose, plasma 
levels of 0.049ug/ml (0.14uM) to 
0.314ug/ml (0.93uM).17 Normal 
adult dose is 150mg every 8-12 h. 
Localizes to liver and fat deposits. 
Lung distribution not known.18 
3 h17
OC43(1.61, 12.11); NL63(7.32, 
11.71); MERS(9.45, 11.98); 
A59(11.46, 12.44)8
Pros: 1) Levels at low range of EC50 2) 
Good clinical experience                                                                  
Cons: 1) Levels at low range of EC50 
2) Short half life 3) Lung 
accumulation unknown
Astemizole1                                                                               
(458.6)
0.002ug/ml (0.0045uM) to 
0.05ug/ml (0.11uM).6 High lung 
accumulation of both forms. Daily 
oral dosing of dogs with 1mg/kg for 
6 weeks resulted in 725 to 1020-fold 
of AST and DES-AST combined over 
plasma level.19
20 to 26 h (Astemizole)                       
9 days (Desmethyl-
astemizole)6
MERS(4.884); SARS(5.591)1
Pros: 1) Lung levels within range of 
EC50 2) High lung accumulation 3) 
Good clinical experience                                                               
Cons: 1) Short half-life 2) Withdrawn 
due to rare fatal arrythmias
Chlorphenoxamine HCl1                                                              
(340.3)
After 40mg oral dose, plasma levels 
below 10ng/ml (0.03uM) (limit of 
detection). Based on 
diphenhydramine, lack of significant 
lung uptake.20
2-9 h 
(diphenhydramine 
analog)4
MERS(12.646): SARS(20.031)1
Pros: 1) Good clinical experience                            
Cons: 1) Levels far below EC50 2) 
short half-life 3) assume poor lung 
accumulation based on 
diphenhydramine                                                           
Chloropyramine8                                                        
(289.8)
Not approved for use in US.  In 
dogs, 7.5mg/ml oral 
administration results in peak 
plasma levels of 234ng/ml 
(0.8uM).21 Lung approximately 80-
fold higher than plasma level 
after 6h in mice.22
21 h21
OC43(1.79, >20); NL6(14.21, >20); 
MERS(14.21, >20); A59(2.42, >20)8
Pros: 1) Lung levels within range of 
EC50 2) High lung accumulation 3) 
Suitable half-life Cons: 1) Not 
approved for use in humans
Conessine8                                     
(356.6)
No pharmacokinetic data available. 
Based on a N-demethylate 
derivative (DMNG-3) in rats, an oral 
40mg/kg dose resulted in 2.06ug/ml 
(5.78uM); 20mg/kg dose 0.97ug/ml 
(2.72uM).23 After oral 
administration to mice distributes 
to all tissues but accumulates in 
GI and liver, with moderate to low 
accumulation in lungs.23
15 h23
OC43(2.34, >20); NL63(10.75, >20); 
MERS(4.98, >20); A59(11.46, >20)8
Cons 1) Experimental 2) Moderate to 
low accumulation in lungs
Promethazine HCl1                                                                     
(320.9)
0.05ug/ml (0.16uM) to 0.4ug/ml 
(1.2uM)6
8 to 15 h6
MERS(11.802); SARS(7.545)1; SARS-
CoV-2(10.44, >42.59)40
Pros: 1) Levels at low range of EC50 2) 
Good clinical experience                                                                  
Cons: 1) Levels at low range of EC50 
2) Lung accumulation unknown
An
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Benztropine mesylate1                          
(403.5)
1.5mg single oral dose 2.5ng/ml 
(0.006uM)24 7 h
24 MERS(16.627); SARS(21.611)
1; SARS-
CoV-2(17.79, >50)40
Pros: 1) Good clinical experience                              
Cons 1) Levels far below EC50 2) short 
half-life 3) lung accumulation 
unknown                                                            
An
ti-
am
oe
bi
c
Emetine1,8                                       
(553.6)
Peak plasma levels following oral 
ipecac is 9.6ug/ml (0.02uM).25 High 
lung accumulation26  
24 to 48 h6
OC43(0.30, 2.69); NL63(1.43, 3.63); 
MERS(0.34, 3.08); A59(0.12, 3.51)8                                                           
MERS (0.014); SARS (0.051)1;SARS-
CoV-2(<0.01, .7)42
Pros: High lung accumulation 3) 
Good clinical experience 4) Long half-
life                                                   Cons: 
1) Lung levels below range of EC50 
(may be overcome by lung 
accumulation) 2) Induces emesis in 
patients 
Pr
ot
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n 
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r
Lycorine8                                         
(287.3)
Peak plasma concentration in mice 
5.1ug/ml (17.75uM). Distributes 
widely to tissues, including lungs, 
but then reduced to undetectable 
levels over 2 h.27
3 to 6 h27
OC43(0.15, 4.37); NL63(0.47, 3.81); 
MERS(1.63, 3.14); A59(0.31, 3.51)8; 
SARS-CoV-2(0.31, >40)43
Cons: 1) Experimental 2) Short half-
life
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Tetrandrine8                                  
(622.8)
Oral administration of 100mg results 
in 67ng/ml (0.1uM) peak plasma 
concentration. Berbamine is a key 
metabolite, with same study 
showing 33ng/ml (0.05uM).28 
Concentrated 8-fold in lungs 
compared to plasma.29
24hr28
OC43(.29, >20); NL63(2.05, >20); 
MERS(12.68, >20); A59(4.81, >20)8
Cons: 1) Experimental in US. 
Approved in China for treatment of 
silicosis.
In
te
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Tilorone8                                         
(483.5)
At a well tolerated 10mg/kg dose, 
peak plasma concentration is 
135ng/ml (0.28uM) in males and 
92.3ng/ml (0.19uM) in females. At 
2mg/kg, 50.5ng/ml (0.10uM) and 
17.5ng/ml (0.036uM), males and 
females, respectively.30 In mice 20-
fold higher accumulation in lung 
than serum.31
20 h30 
OC43(0.32, >20); NL63(6.89, >20); 
MERS(10.56, >20); A59(16.11, >20)8
Cons: 1) Experimental in US.                                                                
Marketed as Amixin, Lavomax as an 
antiviral in Russia
An
tip
la
te
le
t
Ticlopidine8                                   
(263.8)
For reduction of risk nonfatal stroke 
normal dose is 250mg twice daily. 
Oral administration of 250mg results 
in peak plasma concentration of 
0.08ug/ml (0.30uM) to 0.8ug/ml 
(3.03uM).32 Lung distribution not 
known.
20 to 50 h32
OC43(1.41, >20); NL63(15.65, >20); 
MERS(11.25, >20); A59(14.28, >20)8
Pros: Within range of EC50 2) Good 
clinical experience 3) Long half-life                                                   
Cons: 1) Lung accumulation 
unknown 2) Intensive patient 
management 
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Triflupromazine HCl1                 
(388.9)
No PK data. Assume comparable to 
chlorpromazine of this class. 23 to 37 h
4 MERS(5.758); SARS(6.398)1
Pros: 1) Comparable to Tier 1 low 
potency antipsychotics                                                          
Cons: 1) Discontinued in US
Anisomycin1                                  
(265.3)
NR* NR MERS(0.003); SARS(0.191)1
Cons: 1) Experimental 2) High 
toxicity 
Salinomycin sodium8                   
(773.0)
NR NR
OC43(0.29, 1.97); NL63(5.71, 2.41); 
MERS(5.49, 3.84); A59(5.16, 2.45)8
Cons: 1) High toxicity 2) Not used in 
humans. Animal feed additive.
Valinomycin8                             
(1,111.3)
NR NR
OC43(4.43, 6.15); NL63(1.89, 4.12); 
MERS(6.07, 5.88); A59(6.78, 5.11)8
Cons: 1) High toxicity
Dihydrocelastryl 
diacetate8              
(536.7)
NR NR
OC43(1.17, >20); NL63(0.65, >20); 
MERS(10.58, >20); A59(4.24, >20)8
Cons: 1) Experimental use
Cetylpyridinium        
chloride8                       
(340.0)
NR NR
OC43(4.31, 8.23); NL63(1.24, 8.52); 
MERS(0.69, 8.14); A59(7.86, 8.19)8
Cons: 1) Cationic disinfectant 2) 
Ingredient of mouthwash and poorly 
absorbed 3) No systemic PK data
Monensin sodium8                      
(692.9)
NR NR
OC43(3.81, >20); NL63(1.54, >20); 
MERS(3.27, >20); A59(0.18, >20)8
Cons: 1) High toxicity 2) Not used in 
humans.
Oligomycin8                                   
(791.1)
NR NR
OC43(0.19, 6.56); NL63(2.63, 4.26); 
MERS(0.21, 5.16); A59(6.43, 6.78)8
Cons: 1) High toxicity
Cycloheximide1,8                           
(281.4)
NR NR
OC43(0.43, 3.12); NL63(2.64, 3.24); 
MERS(2.56, 2.96); A59(5.21, 3.19)8                                                             
MERS(0.189); SARS(0.043)1; SARS-
CoV-2(0.58) 44
Cons: 1) High toxicity
Exalamide8                                    
(221.3)
NR NR
OC43(1.48, >20); NL63(17.49, >20); 
MERS(15.91, >20); A59(16.39, >20)8
Topical application (anti-fungal).                                       
Not used systemically.
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Phenylmercuric 
acetate8                  
(336.7)
NR NR
OC43(2.17, 5.35); NL63(6.79, 5.47); 
MERS(6.44, 5.39); A59(6.81, 5.97)8
Cons: 1) High toxicity
Terconazole1                                  
(532.5)
Topical preparation NR MERS(12.203); SARS (15.327)
1; SARS-
CoV-2(16.14, 41.46)40
Cons: Topical antifungal
An
ti-
pi
nw
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m
Pyrvinium pamoate8                  
(769.9)
Single oral dose of 350mg. Not 
absorbed after oral 
administration.33
Not absorbed33
OC43(3.21, >20); NL63(3.35, >20); 
MERS(1.84, 19.91); A59(4.12, 
19.98)8
Oral anti-helminth                                                          
Cons: 1) Plasma levels far below EC50 
(not absorbed)
Fluphenazine HCl1                       
(510.4)
0.001ug/ml (0.002uM) to 
0.004ug/ml(0.008uM)6
8 to 28 h4                            
(depending on route 
and formulation)
MERS(5.868); SARS(21.431)1; SARS-
CoV-2(8.98, 20.02)40
Cons: 1) Plasma levels far below EC50
Fluspirilene1                                  
(475.6)
Single 2mg intramuscular dose 
resolted in peak plasma of 
0.000083ug/ml (0.0001uM) to 
0.000280ug/ml (0.0006uM)34
NR MERS(7.477); SARS(5.963)
1; SARS-
CoV-2(5.32, 30.33)40
Cons: 1) Plasma levels far below EC50
Thiothixene1                                  
(443.6)
0.001ug/ml (0.002uM) to 
0.025ug/ml (0.056uM)6 34 h
4 MERS(9.297); SARS(5.316)1 Cons: 1) Plasma levels far below EC50
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Berbamine8                                  
(608.7)
Oral administration of 100mg results 
in peak plasma of 33ng/ml 
(0.05uM).28 Lung distribution not 
known.
39 h28  
OC43(1.48, >20); NL63(9.46, >20); 
MERS(13.14, >20); A59(10.91, >20)8
Cons: 1) Experimental use
Ch
al
co
ne
4'-Hydroxychalcone8                      
(224.3)
Experimental with minimal 
information. No PK data
NR
OC43(1.52, >20); NL63(7.25, >20); 
MERS(10.23, >20); A59(9.75, >20)8
Cons: 1) Experimental use
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Antimycin A8                                  
(548.6)
NR NR
OC43(1.65, 3.62); NL63(6.05, 4.21); 
MERS(6.89, 4.32); A59(5.42, 3.98)8
Cons: 1) High toxicity
Lo
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Diperodon8                                     
(433.9)
NR NR
OC43(1.71, 14.3); NL63(4.91, 13.6); 
MERS(8.77, 14.2); A59(1.98, 14.4)8
Used as topical anaesthetic
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E-64-D1                                            
(342.4)
Not known Not known MERS(1.275); SARS(0.760)1 Cons: 1) Experimental use
Be
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Harmine8                                        
(212.3)
Neurotoxin NR
OC43(1.9, >20); NL63(13.46, >20); 
MERS(4.93, >20); A59(13.77, >20)8
Cons: 1) High toxicity 2) 
Experimental use
An
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Loperamide5,8                                     
(513.5)
Standard oral dose of 2mg results in 
peak plasma concentration of 
0.002ug/ml (0.0039uM).3 Abuse 
with toxicity using higher doses can 
exceed 100ng/ml (0.038uM). Lung 
accumulation not known. In one 
overdose study, lung not tested but 
5-fold increase in liver over 
peripheral blood.35
11 h4
 MERS(4.8, 15.5); SARS(5.9, 53.8); 
229E(4.0, 25.9)5                                                                       
OC43(1.86, 18.7); NL63(6.47, 
18.27); MERS(4.82, 18.9); 
A59(10.65, 18.9)8                                                             
Cons: 1) High toxicity 2) Levels far 
below EC50
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Phenazopyridine8                         
(213.2)
Following standard 200mg oral 
dose, peak plasma levels of 
0.012ug/ml (0.056uM).36 No 
substantial accumulation in the lung 
(maximum 1.8-fold at 2 h post 
100mg/kg dose in rats).37
50 min36
OC43(1.90, <20); NL63(2.02, >20); 
MERS(1.93, >20); A59(0.77, >20)8
Cons: 1) At lower limit of EC50 2) 
Does not accumulate in lungs 3) 
Short half life
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Pristimerin8                                   
(464.6)
Following and oral dose of 2mg/kg 
in rats, peak plasma level 0.19ug/ml 
(0.41uM).38 Tissue distribution is 
not known.
5h38
OC43(1.99, >20); NL63(1.63, >20); 
MERS(13.87, >20); A59(9.17, >20)8
Cons: 1) Experimental 2) Levels far 
below EC50
M
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cl
e 
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Zoxazolamine8                             
(168.6)
Single oral dose of 0.75 to 1g results 
in peak plasma levels of 3ug/ml 
(17.8uM) to 12ug/ml (71.2uM).39 
Lung accumulation not known, but 
no accumulation in other multiple 
tissues (muscle, kidney, liver, brain 
or fat) in dogs.39
Rapid (completely gone 
by 7 h39)
OC4391.39, >20); NL63(13.51, >20); 
MERS(14.21, >20); A59(16.45, >20)8
Cons: 1) High liver toxicity
NR: Not relevant
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